Additional Relevant Details Pfizer Inc.  and Eli Lilly and Company announced today that they are preparing to resume the Phase 3 clinical program for tanezumab. A partial clinical hold has been in place for tanezumab and all other anti-nerve growth factor antibodies since December 2012 due to adverse changes in the sympathetic nervous system of mature animals. Studies in terminal cancer pain were allowed to proceed.